News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Novartis Corporation Superbug Drug Gets Wider EU Approval
September 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Sept 5 (Reuters) - Novartis (NOVN.VX: Quote, Profile, Research) on Wednesday said its anti-superbug drug Cubicin had received European approval to extend use to treat two additional types of hospital infections.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Earnings
Lilly Faces Triple Threat of Drug Pricing Pressure as CEO Emphasizes Value
August 7, 2025
·
3 min read
·
Annalee Armstrong
IN PARTNERSHIP WITH CRESSET
From Chat Bots to World Order: The Race for the 21st Century’s Operating System
August 7, 2025
·
1 min read
·
Lori Ellis
IN PARTNERSHIP WITH IQVIA
We Don’t Own Patient Data–We’re Just Babysitting It
July 31, 2025
·
1 min read
·
Lori Ellis
Regulatory
Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients
July 25, 2025
·
2 min read
·
Tristan Manalac
